EloraTZP Phase 2b at EASD 2026: What Lilly Reported for Eloralintide Plus Tirzepatide

What Did Lilly Report for EloraTZP at EASD 2026?

On 30 September 2026, at the 62nd Annual Meeting of the European Association for the Study of Diabetes (EASD) in Milan, Eli Lilly reported Phase 2b results for EloraTZP, an investigational combination of eloralintide and tirzepatide.[1] Our earlier EASD 2026 preview flagged that this dataset was coming; this article covers what was actually disclosed.

The study enrolled 367 adults with obesity or overweight and type 2 diabetes and reported outcomes at 48 weeks. Per Lilly, all four eloralintide-plus-tirzepatide dose combinations met the primary and secondary endpoints. Mean body-weight change across the four combinations ranged from 13.2% to 23.3%, with A1C reductions of 2.2 to 2.9 percentage points from a baseline of 8.1%.[1][2] Everything in this paragraph is company-reported topline data; the full peer-reviewed paper is not yet available to verify subgroup and safety detail.

How Did the Combination Compare With Tirzepatide Alone?

The comparison that matters methodologically is the within-trial one: the combination arm against tirzepatide 15 mg, the active comparator already covered in our tirzepatide research overview. The efficacy estimand used for these figures estimates outcomes had every participant remained on treatment for the full 48 weeks, which generally yields larger effects than a treatment-regimen estimand that counts discontinuations. Researchers should therefore read the headline numbers alongside the discontinuation data below.

What Did the Tolerability and Discontinuation Data Show?

Tolerability is where the dataset is most nuanced. Reporting of the Lilly data states that discontinuations due to adverse events ranged from 10.8% to 27.0% across the EloraTZP arms, against 2.9% for tirzepatide alone.[2] Gastrointestinal events were the most commonly reported adverse events and clustered during dose escalation, according to coverage of the presentation.[3] We could not confirm event-specific incidence figures from the primary release text, so we do not quote them here.

That pattern fits a broader theme of the meeting. A Pharmaceutical Technology podcast published 8 October 2026 summarised the EASD view that efficacy is no longer the main differentiator among incretin-class agents and that tolerability is becoming central to how new candidates are positioned.[4] Amylin-based combinations were one of the meeting's major threads.

How Does EloraTZP Relate to Retatrutide?

The two programmes represent different design philosophies inside the same company. Retatrutide (LY3437943) is a single molecule engineered to act on three receptors — GLP-1, GIP and glucagon. EloraTZP instead pairs two separate agents, layering amylin-receptor agonism onto tirzepatide's existing dual GIP/GLP-1 activity. Mechanistically, the amylin arm is an additional pathway rather than a third receptor on one scaffold.

There is no head-to-head trial of EloraTZP and retatrutide, and coverage of the EASD data says as much.[3] The populations, durations and analysis conventions differ: retatrutide's TRIUMPH-2 reported 80-week data in a type 2 diabetes population (our TRIUMPH-2 summary), whereas EloraTZP's Phase 2b is a 48-week mid-stage study. Cross-trial comparison is hypothesis-generating at best. For another amylin-combination programme, see retatrutide vs CagriSema.

What Happens Next, and What Is the Regulatory Status?

Lilly said it plans to move EloraTZP into Phase 3 testing in the fourth quarter of 2026.[2] Eloralintide monotherapy has its own earlier Phase 2 dataset, reported at ObesityWeek 2025 in adults without type 2 diabetes (20.1% body-weight change at the 9 mg dose at 48 weeks), a different population from this trial.[3] The programme is registered on ClinicalTrials.gov, including NCT06603571.[5]

EloraTZP has no marketing authorisation from the FDA, MHRA, EMA or any other regulator. Nothing in this summary is a statement about safety or suitability for any use outside controlled clinical trials.

What Should Researchers Take From This?

This is licensed-pharma development reporting, kept deliberately separate from research-use compounds. For laboratory researchers working on the receptor pharmacology these programmes build on, the useful points are the continuing shift toward multi-pathway designs and the weight placed on tolerability endpoints, not any claim about outcomes in people. Velox Peptides supplies retatrutide strictly as an HPLC-verified in vitro research reagent; it does not list eloralintide or EloraTZP.

This compound is supplied as a research reagent only. It is not a medicine and has not been evaluated by the MHRA or FDA for use in our products. Not for human or veterinary use. See our Research Use Policy and MHRA Statement.

Frequently Asked Questions